Title(s): M.D.
Current Position/Designation: Post-doctoral Associate
Institutional Affiliation: Department of Neurosurgery, Duke University, Durham, NC, USA
Active Email Address: Tarek.boudargham@duke.edu
Social Media Handle (Any and/or optional): X: Tarekbdargham
Telephone Number (WhatsApp): +961 70 303 885
I am a Postdoctoral Associate at the Preston Robert Tisch Brain Tumor Center at Duke University, where my work integrates basic immunology and clinical neuroscience to improve outcomes for patients with brain tumors. My research focuses on the development of dendritic cell-based immunotherapies for glioblastoma and the characterization of the tumor immune microenvironment using murine models and patient-derived tissues. In parallel, I conduct clinical research on neurocognitive outcomes in patients with brain metastases, examining how multimodal therapies—including radiation and systemic treatments—affect overall cognitive function and quality of life. These complementary research efforts share a central aim of advancing tumor-directed therapies while preserving neurological function and long-term quality of life.
Postdoctoral Associate at the Preston Robert Tisch Brain Tumor Center, Duke University, conducting basic and translational research in neuro-oncology
Led clinical research across multiple institutions focused on identifying and mitigating long-term cognitive sequelae of radiotherapy and systemic treatments in patients with CNS malignancies
Conducted human tissue analyses to evaluate immune shifts in matched primary and recurrent glioblastoma
Expertise in dendritic cell–based immunotherapies, antigen-targeted vaccine strategies, and glioma immune profiling
Skilled in brain tumor histopathology evaluation, and molecular immune characterization
Experience integrating laboratory and clinical data to investigate neuroimmune mechanisms underlying treatment response
Conducted multi-site research across U.S. and Middle Eastern institutions involving the central nervous system
Proficient in bridging basic science and clinical endpoints to inform neurorehabilitation and survivorship frameworks